louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05213338: Wear-documentation and Orthodontic Appliance Compliance
Official title: Effect of Thermosensory Wear-documentation on Removable Orthodontic Appliance Compliance
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Orthodontic Appliance Complication
Keywords: orthodontics
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: City of Vantaa
First posted: 2022-01-28
Enrollment: 52
Sex: ALL
Minimum age (years): 10
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized controlled trial aims to evaluate whether thermosensory wear-time documentation improves patient compliance of removable orthodontic appliances treated in a public health care clinic. The patients are children and adolescents.

Detailed description: Qualitative subjective evaluation of appliance wear comfort and compliance is recorded, in addition to objective wear-time documentations.

Eligibility criteria: Inclusion Criteria:

* orthodontic treatment with removable appliances planned

Exclusion Criteria:

* non-compliance to participate in the study

Primary outcomes:
measure: Treatment-time
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Patient satisfaction
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Vantaa
country: Finland
facility: City of Vantaa
Study officials:
affiliation: University of Helsinki
name: Heidi Arponen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05864638: Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study
Official title: Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study （OCIN-AIS-EVT REGISTRY）
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Ischemic Stroke
Large Vessel Occlusion
Thrombectomy
Thrombosis
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2023-05-18
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All acute ischemic stroke patients receiving endovascular treatment

Brief summary: A Multicenter Registry of Endovascular Treatment for Acute Ischemic Stroke.

Detailed description: The OCIN-AIS-EVT REGISTRY is a prospective, multicenter, blinded outcome evaluation, observational trial, and aims to determine the functional outcomes and safety of endovascular treatment for AIS, due to vessel occlusion in anterior and posterior circulation, in routine clinical practice.

The primary endpoint is functional outcome, defined as a shift (improvement) in scores on the modified Rankin scale (mRS) at 90 days (±7 days).

Eligibility criteria: Inclusion Criteria:

1. Acute ischemic stroke caused by anterior or posterior circulation vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA)
2. Undergo intravascular therapy (i.e. access to a cath lab and an arterial puncture)
3. The patient or his/her legal representative agreed to participate in the study and has signed the informed consent.

Exclusion Criteria:

1) No exclusion criteria

Primary outcomes:
measure: Functional outcome
timeFrame: 90days
Secondary outcomes:
measure: Dichotomized modified Rankin scale (mRS)
timeFrame: 90days
measure: NIHSS at 24 hours
timeFrame: 24 hours post-procedure
measure: NIHSS at 7 days
timeFrame: 7 days post procedure
measure: Reperfusion outcome
timeFrame: Immediately post-procedure
measure: Early successful revascularization rate
timeFrame: During procedure
measure: Target vessel recanalization rate
timeFrame: at 7 days post-procedure
Other outcomes:
measure: Death
timeFrame: 7 days and 90 days
measure: Intracerebral hemorrhage(ICH)
timeFrame: 90 days
measure: Procedure related complication
timeFrame: within 30 days after procedure
measure: Device related complications
timeFrame: within 30 days after procedure
measure: adverse events of special interest
timeFrame: within 90 days
Locations:
city: Shanghai
country: China
facility: Jianimin Liu
Study officials:
affiliation: Changhai Hospital
name: Jianimin Liu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05241938: PSLT Compared to Prostaglandin Analogue Eye Drops
Official title: Computer-guided Selective Laser Trabeculoplasty (PSLT) in the Treatment of Ocular Hypertension and Open-angle Glaucoma Compared to Prostaglandin Analogue Eye Drops: a Non-inferiority Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Open Angle Glaucoma
Ocular Hypertension
Lead sponsor: Federal University of Rio Grande do Sul
Sponsor class: OTHER
First posted: 2022-02-16
Enrollment: 75
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the efficacy of PSLT and the topical use of prostaglandin-like hypotensive eye drops in the treatment of ocular hypertensive or glaucomatous patients in decreasing intraocular pressure and measuring changes in functional, structural and biomechanical parameters evaluated by computerized perimetry and optical coherence tomography (OCT) related to pressure change resulting from treatments

Detailed description: Patients with a diagnosis of ocular hypertension or bilateral glaucoma, naive or on treatment with up to two classes of hypotensive eye drops will be invited to participate in the study.

These patients will have both eyes included in the study. A randomization will be made to allocate one eye to receive treatment with PSLT (treatment group), while the contralateral eye will receive treatment with prostaglandin eye drops (control).

Patients will be followed up for 12 months and periodically tonometry, computerized perimetry, water overload test and OCT will be performed.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of ocular hypertension (IOP ≥ 24 mmHg in both eyes) or diagnosis of open-angle glaucoma (POAG) in both eyes
* Proper visualization of angle structures and 360 degree open angles in both eyes
* No previous intraocular surgery with the exception of phacoemulsification with intraocular lens implantation
* No use of systemic medications known to increase IOP

Exclusion Criteria:

* Patients using more than two glaucoma medications
* Evidence of any other eye disease that could affect IOP measurement
* Diagnosis of other types of glaucoma
* Patient with mean deviation (MD) less than -12 decibels (dB) on visual perimetry (severe disease)
* Patients with unilateral glaucoma

Primary outcomes:
measure: Intraocular pressure change
timeFrame: 1 week, 2 months, 9 months, 12 months
Secondary outcomes:
measure: Structural damage
timeFrame: 1 week, 9 months, 12 months
measure: Functional damage
timeFrame: 1 week, 9 months, 12 months
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Universidade Federal do Rio Grande do Sul
state: RS
Study officials:
affiliation: UFGRS
name: Helena Pakter, MD. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06241638: Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers
Official title: Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined With Dapagliflozin as Type Two Diabetes Mellitus Routine Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Al-Balqa Applied University
Sponsor class: OTHER
First posted: 2024-02-05
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The current study was conducted to evaluate the prognostic implications of vitamin B12 admission on BMI and HbA1c levels in type 2 diabetic patients treated with Dapagliflozin as a routine medication.

Detailed description: Eighty diabetic patients were enrolled in this study; 37 females and 43 males with inclusion criteria of vitamin B12 levels less than 233 ng/ml. The participants were divided into two groups, the Dapagliflozin group (active comparator group) received only the diabetic-controlling drug Dapagliflozin 10 mg/daily orally for twelve months, whereas, vitamin B12 and Dapagliflozin group (Experimental group) received Vit. B12 supplements as methylcobalamin 500 µg orally once daily with Dapagliflozin 10 mg/daily orally for twelve months. Glycemic control was measured by monitoring levels of HbA1c and Vitamin B12 in the participant's blood four times at time intervals of three months during the study period. Additionally, the weight measurements were recorded during the study period at time intervals of three months and BMI was calculated. The data obtained was treated by statistical analysis using SPSS software (version 20) for the significant correlation of the independent variables of the study groups after vitamin B12 supplementation.

Eligibility criteria: Inclusion Criteria:

* Diabetic patient treated with Dapagliflozin

Exclusion Criteria:

* The levels of Vitamin B12 more than 200 ng/ml

Primary outcomes:
measure: HbA1c in the two groups
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Salt
country: Jordan
facility: Walid Aburayyan
Study officials:
References:
Clinical trial NCT03579238: Entrainment Between Clinician and Patient During Palpation
Official title: Entrainment Interaction Between Physician and Patient During Palpation of the Cranium
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Doctor Patient Relation
Lead sponsor: Western University of Health Sciences
Sponsor class: OTHER
First posted: 2018-07-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Intrasubject sequential intervention design
Primary purpose: BASIC_SCIENCE

Brief summary: This study will assess the physiological interaction between the palpating clinician and a research participant using a laser Doppler flow meter to detect changes in blood flow parameters.

Detailed description: Research participants will lie on their backs on a soft table while a licensed physician, with special training in osteopathic palpation and manipulation approaches, touches, and administers a slight inhibition of occipital bone motion for five minutes per stage. Both will have a non invasive skin sensor (probe), called a laser Doppler flow meter, attached to their forehead to detect changes in subcutaneous blood flow velocity. The signal from the device will be augmented and transmitted for display onto a digital polygraph recorder. Then, using Fourier transformation software, the signal will be displayed as a graph for spectral analysis to determine the effect on specific wave forms related to autonomic activity. The interaction between the two individuals will be assessed for evidence of entrainment phenomenon, i.e., the influence of one biorhythm upon another.

Eligibility criteria: Inclusion Criteria:

* healthy adult that can lie on his or her back on a padded table without moving for 35 minutes.

Exclusion Criteria:

* head trauma within the last six months, seizure disorder, pregnant, brain disease or injury, using beta or alpha blocker medication, unable to lie still for 35 minutes, allergy to the hypoallergenic sticky tape used to attach sensor to forehead

Primary outcomes:
measure: Entrainment of still points between clinician and research participant
timeFrame: within 1 minute of each other (arbitrary designation)
Secondary outcomes:
Other outcomes:
Locations:
city: Pomona
country: United States
facility: Western University of Health Sciences
state: California
Study officials:
affiliation: Western University of Health Sciences
name: Michael Seffinger, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02137538: Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole
Official title: Randomization to Letrozole vs. Anastrozole in Short Pubertal Males
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Short Stature
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2014-05-14
Enrollment: 79
Sex: MALE
Minimum age (years): 10
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.


Eligibility criteria: Inclusion Criteria:

* Current height less than 5th percentile AND/OR
* Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
* Evidence of puberty: physical signs and serum luteinizing hormone \> 0.3 IU/L and testosterone \> 15 ng/dl

Exclusion Criteria:

* Bone age reading more than 14.0 years
* Follicle stimulating hormone \> 20 IU/L

Primary outcomes:
measure: Predicted Adult Height at Year 3
timeFrame: Year 3
Secondary outcomes:
measure: Serum Testosterone
timeFrame: Baseline, year 3
measure: Dihydrotestosterone
timeFrame: Baseline, year 3
measure: Androstenedione
timeFrame: Baseline, year 3
measure: Luteinizing Hormone
timeFrame: Baseline, year 3
measure: Follicle Stimulating Hormone
timeFrame: Baseline, year 3
measure: Insulin-like Growth Factor Type 1
timeFrame: Baseline, year 3
measure: Inhibin B
timeFrame: Baseline, year 3
measure: Estradiol
timeFrame: Baseline, year 3
measure: Estrone
timeFrame: Baseline, year 3
measure: Number of Adverse Events Related to Acne or Bone Fracture
timeFrame: 3 years
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Lucile Packard Children's Hospital
state: California
Study officials:
affiliation: Stanford University
name: E Kirk Neely, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Laura K Bachrach, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Walter A Zegarra, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Neely EK, Kumar RB, Payne SL, Ranadive SA, Suchet DI. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab. 2014 Nov;99(11):4086-93. doi: 10.1210/jc.2014-2432. Epub 2014 Aug 19.
Clinical trial NCT00324038: Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
Official title: An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteoarthritis
Keywords: OA
Elderly
Pain
OA of the hips and/or knees
Lead sponsor: Napp Pharmaceuticals Limited
Sponsor class: INDUSTRY
First posted: 2006-05-10
Enrollment: 219
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).


Eligibility criteria: Inclusion Criteria:

* Either sex aged 65 or above
* Diagnosis of OA of the hip and/or knee
* Severe pain requiring step two medication
* Taking maximum dose of paracetamol

Exclusion Criteria:

* Painful disease of the joints other than OA
* Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal anti-inflammatory agents (NSAIDS)
* Subjects taking cyclooxygenase (COX) II selective inhibitors

Primary outcomes:
measure: Average Daily Pain Scores - BS11 Pain Scores.
timeFrame: every day over a 12 week study duration.
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United Kingdom
facility: Napp Pharmaceuticals Ltd
Study officials:
name: Prof Philip Conaghan
role: PRINCIPAL_INVESTIGATOR
References:
citation: Conaghan PG, O'Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage. 2011 Aug;19(8):930-8. doi: 10.1016/j.joca.2011.03.011. Epub 2011 Apr 6.
Clinical trial NCT04961138: Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
Official title: Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma: an Open, Random, Multicenter, Prospective Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hepatocellular Carcinoma Stage III
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-07-14
Enrollment: 164
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.


Eligibility criteria: Inclusion Criteria:

* Age 18-80 years old, both gender
* Confirmed diagnosis of stage III hepatocellular carcinoma(HCC)
* Fulfill the criteria of surgery
* No other severe comorbidity
* Eastern Cooperative Oncology Group score(ECOG) 0-2
* Expected survival \> 3months
* Informed consent obtained.

Exclusion Criteria:

* Received chemoradiotherapy or other antineoplastic drugs
* Severe cirrhosis with Child-Pugh score \>10
* Total bilirubin \> 1.5 times upper limit, AST or ALT \> 2times upper limit, indocyanine green retention rate after 15 min(ICG15) \>=40%;
* Not fulfill the surgery criteria
* Received major surgery within 1month
* History of other tumor
* Participate other clinical trial within 1month
* Drug or alcohol abuse, AIDS
* Uncontrollable epileptic seizure or cognitive disorder
* Severe allergy
* Other unsuitable conditions.

Primary outcomes:
measure: 1-year disease free survival
timeFrame: 1 year
Secondary outcomes:
measure: 1-year overall survival
timeFrame: 1 year
measure: Rate of R0 resection
timeFrame: 1 week
measure: objective response rate
timeFrame: up to 2 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01096238: Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months
Official title: Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Influenza
Keywords: The immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in adults after half a year will be analyzed and discussed.
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2010-03-31
Enrollment: 185
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: PROBABILITY_SAMPLE
Study population: age\>=18 who had AdimFlu-S(A/H1N1) injection

Brief summary: In the spring of 2009, a recently emerged novel influenza A (H1N1) virus was first identified in Mexico and USA and it has continued to spread globally. The rapid global spread of a novel influenza A (H1N1) 2009 virus prompted the World Health Organization (WHO), on 11 June 2009, to declare the first influenza pandemic in 41 years. In Taiwan, a clinical study to assess the immunogenicity and safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in healthy volunteers has already been completed. In the previous study, we found that a single 15 mcg HA dose of the AdimFlu-S (A/H1N1) vaccine induces a protective immune response in most adults, including those \> 60 years of age (\>70%). Our current study aims to follow-up subjects who received Influenza Virus Vaccine, AdimFlu-S (A/H1N1), six months ago. These subjects' serum samples were tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI). The seroconversion is defined as the post-vaccination serum HAI titer had at least 1:40 for subjects who had seronegative pre-vaccination or a four-fold or greater increase in HAI titers for subjects who had seropositive pre-vaccination serum. The immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in adults after half a year will be analyzed and discussed among the subjects with serum HAI titer had at least 1:40 at least 3 weeks after AdimFlu-S (A/H1N1) injection.


Eligibility criteria: Inclusion Criteria:

* subjects with serum HAI titer had at least 1:40 at least 3 weeks after AdimFlu-S (A/H1N1) injection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: National Taiwan University Hospital
name: Kuo-Chin Huang, Post Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00454038: Study of Collagen Membrane in Guided Bone Regeneration
Official title: Preliminary Study of Hypro-Sorb® F Bilayer Bioabsorbable Membrane for Guided Tissue and Bone Regeneration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Cystectomy
Segmental Growing of Alveolar Tissue
Sinus Lift
Root Amputation and Apicoectomy
Periimplantitis
Keywords: cystectomy
augmentation
sinus
amputation
implant
Lead sponsor: The Baruch Padeh Medical Center, Poriya
Sponsor class: OTHER_GOV
First posted: 2007-03-29
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to investigate the efficacy of Hypro-Sorb® F, a bilayered bioabsorbable membrane in inducing bone regeneration in different dental procedures requiring GBR.

Detailed description: Guided bone regeneration is a procedure used in dentistry for the reconstruction of osseous defects around teeth, dental implants, and prior to implant placement. The main function of the membrane barrier in GBR is to mechanically prevent the undesirable penetration of epithelial cells and fibroblasts to the bone defect area, creating a secluded space where bone regeneration may occur. Resorbable and non-resorbable membranes have been used in GBR. While non resorbable membranes require another surgical procedure for removing the membrane after the healing period, the resorbable membranes have the advantage of transmitting tissue fluids, excluding undesirable cell penetration and sparing an additional unwanted surgical procedure. The aim of this study is to investigate the efficacy of Hypro-Sorb® F, a bilayered bioabsorbable membrane in inducing bone regeneration in different dental procedures requiring GBR.

Eligibility criteria: Inclusion Criteria:

* Cystectomy
* Segmental growing of alveolar tissue
* Lifting of the sinus bottom
* Root amputation
* Apicoectomy
* Filling of the alveolus after resections in prosthetic surgical practice
* Periimplantitis
* Maxillofacial surgery

Exclusion Criteria:

* Inside bone fractures when acrylate adhesives are applied.

Primary outcomes:
measure: expected
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tiberias
country: Israel
facility: The Baruch Padeh Medical Center, Poriya
Study officials:
affiliation: The Baruch Padeh Medical Center
name: Alabuni Emad
role: STUDY_CHAIR
References: